Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Alternative for the neurovirulence test]

Volker Dörsam1, Andreas Schmeel, Konstantin Chumakov

  • 1Chiron-Behring GmbH & Co., D-Marburg.

ALTEX
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards the development of a mucosal vectored vaccine against enterovirus D68.

Virology·2026
Same author

Host-targeted oral avian vaccine virus demonstrates broad antiviral activity and safety in patients.

Frontiers in immunology·2026
Same author

Spacio-Linear Screening for Ligand-Docking Cavities in Protein Structures: SLAM Algorithm.

Life (Basel, Switzerland)·2026
Same author

Viral vector-driven trans-encapsidation of replicon RNAs as a rapid approach for the development of safe and economically attractive anti-enterovirus vaccines.

bioRxiv : the preprint server for biology·2025
Same author

Post-Polio Syndrome: Impact of Humoral Immune Deficiencies, Poliovirus Neutralizing Antibodies, Vitamin D Deficiency.

Vaccines·2025
Same author

Low-grade persistent poliovirus infection in long-term polio survivors diagnosed with post-polio syndrome: diagnostic and clinical implications.

Journal of neurology·2025

The in vivo neurovirulence test (NVT) for oral polio vaccine safety is costly and time-consuming. An in vitro test, MAPREC, shows promise for detecting specific genetic reversions linked to neurovirulence, potentially offering a more efficient alternative.

Area of Science:

  • Virology
  • Vaccine Development
  • Molecular Biology

Background:

  • The in vivo neurovirulence test (NVT) is a mandatory safety test for oral poliomyelitis virus (OPV) vaccine lots.
  • NVT is expensive, time-consuming, and ethically sensitive due to its use of monkeys.
  • Specific genetic reversions in OPV strains correlate with increased neurovirulence in the NVT.

Purpose of the Study:

  • To evaluate the Mutation Analysis by PCR and Restriction Enzyme Cleavage (MAPREC) test as an in vitro alternative for assessing OPV neurovirulence.
  • To investigate the correlation between specific genetic reversions quantified by MAPREC and NVT outcomes.

Main Methods:

  • Utilized the MAPREC test to quantify specific reversions (e.g., 480 G to A, 525 U to C for serotype 1) in OPV lots.
  • Compared MAPREC results with NVT outcomes, particularly focusing on a reversion rate threshold for serotype 3.

Related Experiment Videos

Main Results:

  • For serotype 3, vaccine lots failing the NVT showed a reversion rate of ≥0.9% by MAPREC.
  • Clear reversion rate thresholds for serotypes 1 and 2 have not yet been defined.
  • MAPREC quantifies specific, known mutations linked to neurovirulence but may miss other contributing factors.

Conclusions:

  • Currently, there is insufficient scientific basis to replace the monkey NVT with MAPREC.
  • MAPREC can monitor reversion rates in vaccine lots and assess the impact of production changes.
  • Further studies may establish MAPREC as a reliable in vitro alternative to the NVT.